Follow
jan gerstoft
jan gerstoft
professor clinical virology, University of Copenhagen
Verified email at rh.dk
Title
Cited by
Cited by
Year
Combination antiretroviral therapy and the risk of myocardial infarction
Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group
New England Journal of Medicine 349 (21), 1993-2003, 2003
21012003
Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, J Van Lunzen, ...
Jama 316 (2), 171-181, 2016
16802016
Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study
Data Collection on Adverse Events of Anti-HIV Drugs Study Group
Archives of internal medicine 166 (15), 1632-1641, 2006
14862006
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ...
The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018
14642018
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration
D: A: D Study Group
The Lancet 371 (9622), 1417-1426, 2008
11552008
Survival of persons with and without HIV infection in Denmark, 1995–2005
N Lohse, ABE Hansen, G Pedersen, G Kronborg, J Gerstoft, HT Sørensen, ...
Annals of internal medicine 146 (2), 87-95, 2007
10452007
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of …
AJ Rodger, V Cambiano, T Bruun, P Vernazza, S Collins, O Degen, ...
The Lancet 393 (10189), 2428-2438, 2019
10132019
A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus
TN Kledal, MM Rosenkilde, F Coulin, G Simmons, AH Johnsen, S Alouani, ...
Science 277 (5332), 1656-1659, 1997
6061997
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, ...
Journal of viral hepatitis 21, 34-59, 2014
5562014
Mortality attributable to smoking among HIV-1–infected individuals: a nationwide, population-based cohort study
M Helleberg, S Afzal, G Kronborg, CS Larsen, G Pedersen, C Pedersen, ...
Clinical Infectious Diseases 56 (5), 727-734, 2013
5212013
Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin
P Garred, HO Madsen, U Balslev, BO Hofmann, J Gerstoft, A Svejgaard
The Lancet 349 (9047), 236-240, 1997
5051997
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
HJ Stellbrink, C Orkin, JR Arribas, J Compston, J Gerstoft, ...
Clinical Infectious Diseases 51 (8), 963-972, 2010
4792010
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study
N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ...
European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010
4352010
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study
N Obel, HF Thomsen, G Kronborg, CS Larsen, PR Hildebrandt, ...
Clinical Infectious Diseases 44 (12), 1625-1631, 2007
4222007
Historical epidemiology of hepatitis C virus (HCV) in selected countries
P Bruggmann, T Berg, ALH Øvrehus, C Moreno, CE Brandão Mello, ...
Journal of viral hepatitis 21, 5-33, 2014
4072014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus …
M Sulkowski, C Hezode, J Gerstoft, JM Vierling, J Mallolas, S Pol, ...
The Lancet 385 (9973), 1087-1097, 2015
3692015
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
E DeJesus, G Herrera, E Teofilo, J Gerstoft, CB Buendia, JD Brand, ...
Clinical infectious diseases 39 (7), 1038-1046, 2004
3512004
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study
H Razavi, S Robbins, S Zeuzem, F Negro, M Buti, AS Duberg, ...
The lancet Gastroenterology & hepatology 2 (5), 325-336, 2017
3032017
Clinical course of primary HIV infection: consequences for subsequent course of infection.
C Pedersen, BO Lindhardt, BL Jensen, E Lauritzen, J Gerstoft, ...
British Medical Journal 299 (6692), 154-157, 1989
2981989
Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a …
FN Engsig, ABE Hansen, LH Omland, G Kronborg, J Gerstoft, AL Laursen, ...
The Journal of infectious diseases 199 (1), 77-83, 2009
2832009
The system can't perform the operation now. Try again later.
Articles 1–20